Related references
Note: Only part of the references are listed.Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis
Palak J. Trivedi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2021)
Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis
Kristoffer Kjaergaard et al.
JOURNAL OF HEPATOLOGY (2021)
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
Stefan Traussnigg et al.
WIENER KLINISCHE WOCHENSCHRIFT (2021)
Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation
Omar Y. Mousa et al.
HEPATOLOGY (2021)
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression
Nisreen Nimer et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
Maria Nadinskaia et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease
Chao Sang et al.
JOURNAL OF PROTEOME RESEARCH (2021)
The role of bile acids in cholestatic liver injury
Shi-Ying Cai et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study
Ulrich Baumann et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2021)
Evaluation of the role of bile acids and serotonin as markers of pruritus in children with chronic cholestatic liver disease
Nehal El Koofy et al.
ARAB JOURNAL OF GASTROENTEROLOGY (2021)
Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study
Claire E. Thomas et al.
CANCERS (2021)
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
Arun J. Sanyal et al.
JHEP REPORTS (2021)
Bile acid indices as biomarkers for liver diseases I: Diagnostic markers
Jawaher Abdullah Alamoudi et al.
WORLD JOURNAL OF HEPATOLOGY (2021)
Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis
Weihua Chen et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
HEPATOLOGY (2020)
Alterations of gut microbiome in autoimmune hepatitis
Yiran Wei et al.
GUT (2020)
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
Christopher L. Bowlus et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Modulation of bile acid profile by gut microbiota in chronic hepatitis B
Xiaolin Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Mohammad Shadab Siddiqui et al.
JOURNAL OF HEPATOLOGY (2020)
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Donatella Chianelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies
Jessica L. Petrick et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
Kris Kowdley et al.
JOURNAL OF HEPATOLOGY (2020)
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
Philip N. Newsome et al.
JOURNAL OF HEPATOLOGY (2020)
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis
Christophe Corpechot et al.
JOURNAL OF HEPATOLOGY (2020)
Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals
Jiamin Lou et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Gut microbiome in primary sclerosing cholangitis: A review
Rebecca Little et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2020)
Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD
Giljae Lee et al.
NATURE COMMUNICATIONS (2020)
Treatment of non-alcoholic fatty liver disease - Current perspectives
Anshuman Elhence et al.
INDIAN JOURNAL OF GASTROENTEROLOGY (2020)
The changing epidemiology of liver diseases in the Asia-Pacific region
Martin C. S. Wong et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course
Mark Deneau et al.
JOURNAL OF PEDIATRICS (2019)
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
Maren H. Harms et al.
JOURNAL OF HEPATOLOGY (2019)
The gut microbial influence on cholestatic liver disease
Martin Kummen et al.
LIVER INTERNATIONAL (2019)
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Michael Trauner et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
Paul J. Pockros et al.
LIVER INTERNATIONAL (2019)
A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters
Mao-xu Ge et al.
ACTA PHARMACOLOGICA SINICA (2019)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Michael Trauner et al.
HEPATOLOGY (2019)
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
Gideon M. Hirschfield et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis
Dennis D. Black et al.
HEPATOLOGY COMMUNICATIONS (2019)
Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy
Ruqi Tang et al.
GUT (2018)
Review article: therapeutic bile acids and the risks for hepatotoxicity
K. Ashby et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis
Cyriel Y. Ponsioen et al.
HEPATOLOGY (2018)
INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function
Paolo Comeglio et al.
JOURNAL OF ENDOCRINOLOGY (2018)
Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies
Laura Pimpin et al.
JOURNAL OF HEPATOLOGY (2018)
Total Bile Acid Concentration in Duodenal Fluid Is a Useful Preoperative Screening Marker to Rule Out Biliary Atresia
Tomoya Fukuoka et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Clinical, Pathologic, and Genetic Features of Neonatal Dubin-Johnson Syndrome: A Multicenter Study in Japan
Takao Togawa et al.
JOURNAL OF PEDIATRICS (2018)
Liquid chromatography-mass spectroscopy in the diagnosis of biliary atresia in children with hyperbilirubinemia
Jamie Golden et al.
JOURNAL OF SURGICAL RESEARCH (2018)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2018)
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis
Melissa Palmer et al.
BMC PHARMACOLOGY & TOXICOLOGY (2018)
Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome
Benjamin L. Shneider et al.
HEPATOLOGY COMMUNICATIONS (2018)
Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis
Thomas Horvatits et al.
LIVER INTERNATIONAL (2017)
Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis A Human Pilot Study
David N. Assis et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2017)
Biliary bile acids in hepatobiliary injury - What is the link?
Peter Fickert et al.
JOURNAL OF HEPATOLOGY (2017)
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Peter Fickert et al.
JOURNAL OF HEPATOLOGY (2017)
Bile Acid Synthesis Disorders in Arabs: A 10-year Screening Study
Abdulrahman A. Al-Hussaini et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study
Vinod S. Hegade et al.
LANCET (2017)
Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis
Lukas Bajer et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
New developments in the treatment of primary biliary cholangitis - role of obeticholic acid
Manan A. Jhaveri et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota
Jerome Boursier et al.
HEPATOLOGY (2016)
Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet Cells to Promote Glucose Homeostasis
Divya P. Kumar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis
Xiaoning Wang et al.
JOURNAL OF PROTEOME RESEARCH (2016)
Metabolism of glycerophospholipid, bile acid and retinol is correlated with the early outcomes of autoimmune hepatitis
Chao Zhou et al.
MOLECULAR BIOSYSTEMS (2016)
Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC)
Jochen Mattner
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
ACG Clinical Guideline: Primary Sclerosing Cholangitis
Keith D. Lindor et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Michaela Mueller et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis
Benjamin L. Woolbright et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2015)
Colonic inflammation and secondary bile acids in alcoholic cirrhosis
Genta Kakiyama et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2014)
Bile acids and the gut microbiome
Jason M. Ridlon et al.
CURRENT OPINION IN GASTROENTEROLOGY (2014)
Prospective Evaluation of Ursodeoxycholic Acid Withdrawal in Patients With Primary Sclerosing Cholangitis
Ewa Wunsch et al.
HEPATOLOGY (2014)
Altered profile of human gut microbiome is associated with cirrhosis and its complications
Jasmohan S. Bajaj et al.
JOURNAL OF HEPATOLOGY (2014)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis
Said Al Mamari et al.
JOURNAL OF HEPATOLOGY (2013)
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis
Genta Kakiyama et al.
JOURNAL OF HEPATOLOGY (2013)
Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C
A. Shlomai et al.
JOURNAL OF VIRAL HEPATITIS (2013)
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health
Karin Dilger et al.
JOURNAL OF HEPATOLOGY (2012)
Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease
Derrick E. Fouts et al.
JOURNAL OF HEPATOLOGY (2012)
Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis
Nagoud Schukfeh et al.
JOURNAL OF PEDIATRIC SURGERY (2012)
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis
C. K. Triantos et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Bile Acids Induce Inflammatory Genes in Hepatocytes A Novel Mechanism of Inflammation during Obstructive Cholestasis
Katryn Allen et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis
Peter P. Stanich et al.
DIGESTIVE AND LIVER DISEASE (2011)
Combination of Retinoic Acid and Ursodeoxycholic Acid Attenuates Liver Injury in Bile Duct-Ligated Rats and Human Hepatic Cells
Hongwei He et al.
HEPATOLOGY (2011)
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2011)
High-Dose Ursodeoxycholic Acid Therapy for Nonalcoholic Steatohepatitis: A Double-Blind, Randomized, Placebo-Controlled Trial
Ulrich F. H. Leuschner et al.
HEPATOLOGY (2010)
Differences in presentation and progression between severe FIC1 and BSEP deficiencies
Ludmila Pawlikowska et al.
JOURNAL OF HEPATOLOGY (2010)
High-Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis
Keith D. Lindor et al.
HEPATOLOGY (2009)
Bile-acid-induced cell injury and protection
Maria J. Perez et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Bile composition in Alagille Syndrome and PFIC patients having Partial External Biliary Diversion
Karan M. Emerick et al.
BMC GASTROENTEROLOGY (2008)
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective
Susan N. Cullen et al.
JOURNAL OF HEPATOLOGY (2008)
Mechanisms of disease: inborn errors of bile acid synthesis
Shikha S. Sundaram et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
High-dose ursodeoxycholic acid in primary sclerosing cholangitis:: A 5-year multicenter, randomized, controlled study
R Olsson et al.
GASTROENTEROLOGY (2005)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1
S Katsuma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
KD Lindor et al.
HEPATOLOGY (2004)
Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey
L Okolicsanyi et al.
DIGESTIVE AND LIVER DISEASE (2003)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Share Paper
